HK1249914A1 - 能夠在人脂肪衍生的幹細胞和肝細胞中抑制丙肝病毒複製的肽及其衍生物 - Google Patents

能夠在人脂肪衍生的幹細胞和肝細胞中抑制丙肝病毒複製的肽及其衍生物

Info

Publication number
HK1249914A1
HK1249914A1 HK18109405.0A HK18109405A HK1249914A1 HK 1249914 A1 HK1249914 A1 HK 1249914A1 HK 18109405 A HK18109405 A HK 18109405A HK 1249914 A1 HK1249914 A1 HK 1249914A1
Authority
HK
Hong Kong
Prior art keywords
hepatocytes
hepatitis
virus
peptide
stem cells
Prior art date
Application number
HK18109405.0A
Other languages
English (en)
Inventor
Chen-Lung Lin
Original Assignee
Inno Bio Drug Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inno Bio Drug Development Ltd filed Critical Inno Bio Drug Development Ltd
Publication of HK1249914A1 publication Critical patent/HK1249914A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK18109405.0A 2015-04-16 2018-07-20 能夠在人脂肪衍生的幹細胞和肝細胞中抑制丙肝病毒複製的肽及其衍生物 HK1249914A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/076744 WO2016165101A1 (en) 2015-04-16 2015-04-16 Peptide and its derivatives capable of inhibiting replication of hepatitis c virus in human adipose-derived stem cells and hepatocytes

Publications (1)

Publication Number Publication Date
HK1249914A1 true HK1249914A1 (zh) 2018-11-16

Family

ID=57125559

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18109405.0A HK1249914A1 (zh) 2015-04-16 2018-07-20 能夠在人脂肪衍生的幹細胞和肝細胞中抑制丙肝病毒複製的肽及其衍生物

Country Status (9)

Country Link
US (1) US11254706B2 (zh)
EP (1) EP3283503B1 (zh)
JP (1) JP2018516272A (zh)
KR (1) KR20170137184A (zh)
CN (1) CN107849091B (zh)
AU (1) AU2015391060A1 (zh)
CA (1) CA2982391A1 (zh)
HK (1) HK1249914A1 (zh)
WO (1) WO2016165101A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020024142A1 (en) * 2018-08-01 2020-02-06 Vanford Bio-Drug Development Limited Novel peptides and its derivatives capable of stimulating cytokine release
TWI705818B (zh) * 2019-10-18 2020-10-01 沛爾生技醫藥股份有限公司 肽及其作為製備治療發炎性疾病及疼痛的藥物的用途
EP4047007B1 (en) * 2019-10-18 2024-06-05 Pell Bio-Med Technology Co., Ltd. Peptide and use thereof in preparation of drug for treating inflammatory diseases and pain
CN112759625B (zh) * 2019-10-18 2023-05-05 沛尔生技医药股份有限公司 肽作为制备治疗发炎性疾病及疼痛的药物的用途
WO2023184473A1 (zh) * 2022-04-01 2023-10-05 首创生物技术有限公司 肽用于治疗神经退行性疾病或改善认知功能的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006130553A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Hcv protease inhibitors
KR100794362B1 (ko) * 2006-02-27 2008-01-15 주식회사 임젠 Ｎａｎｏｇ를 이용한 아스트로사이트의 신경줄기세포로의역분화
GB0907698D0 (en) * 2009-05-05 2009-06-10 Univ Singapore Method of modifying serine protease inhibitors
CN104321337B (zh) * 2012-05-25 2017-07-11 永林有限公司 肽及其用途

Also Published As

Publication number Publication date
AU2015391060A1 (en) 2017-10-26
EP3283503A1 (en) 2018-02-21
EP3283503B1 (en) 2020-08-19
WO2016165101A1 (en) 2016-10-20
CA2982391A1 (en) 2016-10-20
KR20170137184A (ko) 2017-12-12
EP3283503A4 (en) 2018-11-14
CN107849091B (zh) 2021-09-10
US11254706B2 (en) 2022-02-22
JP2018516272A (ja) 2018-06-21
US20180134751A1 (en) 2018-05-17
CN107849091A (zh) 2018-03-27

Similar Documents

Publication Publication Date Title
HK1249914A1 (zh) 能夠在人脂肪衍生的幹細胞和肝細胞中抑制丙肝病毒複製的肽及其衍生物
HK1247636A1 (zh) Rna指導的人類jc病毒和其他多瘤病毒的根除
HK1258041A1 (zh) 免疫細胞組合物和使用方法
HK1245838A1 (zh) 用於體外病毒基因組工程的組合物和方法
IL251834A0 (en) Pharmaceutical compositions containing peptide variants and methods of using them
IL244431A0 (en) Pharmacy methods and preparations for the treatment of hepatitis b virus infection
SG11201703569XA (en) HEPATITIS D VIRUS (HDV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
SG11201606819QA (en) Compositions for the inactivation of virus replication and methods of making and using the same
IL261996A (en) A new RNA structure and methods for using it to improve the therapeutic effects of cytotoxic cells and stem cells
PL3416658T3 (pl) Funkcjonalna ludzka komórka śródb‎łonka rogówki i jej zastosowanie
EP3500304A4 (en) USE OF A BCL-XL INHIBITOR AND ONCOLYTIC VIRUS IN THE MANUFACTURE OF ANTITUMUMPRODUCTIVE MEDICAMENT
IL256515A (en) Therapeutic peptides and methods of use thereof
EP3500281A4 (en) USE OF AN IAP INHIBITOR AND ONCOLYTIC VIRUS IN THE PREPARATION OF AN ANTITUMORMEDICAMENT
HK1225645A1 (zh) Pcv2b趨異株疫苗組合物以及使用方法
HK1250950A1 (zh) 曲美他嗪在製備防治肝病的藥物中的用途
IL263265A (en) Use of mesenchymal stem cells and their parts
EP3209780A4 (en) Short non-coding protein regulatory rnas (sprrnas) and methods of use
EP3628674A4 (en) BICYCLIC NUCLEOCAPSID INHIBITORS AND THEIR USE AS MEDICINAL PRODUCTS IN THE TREATMENT OF HEPATITIS B.
FI3380525T3 (fi) Lääkeformulaatioita ja niiden käyttömenetelmiä
SG11201605785XA (en) Stem cell-derived hepatocytes in co-culture and uses thereof
SG11201610731VA (en) A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection
HK1254254A1 (zh) 用於檢測骨髓增殖性疾病中calr突變的方法和組合物
EP3256461C0 (en) UREA AND SULFONAMIDE DERIVATIVES AS HUMAN DDX3 HELICASE INHIBITORS USEFUL IN THE TREATMENT OF VIRAL DISEASES
IL248318A0 (en) Selective inhibitors that have an effect on the hepatitis virus type c
HK1255379A1 (zh) 丙型肝炎病毒免疫原性組合物及其使用方法